{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzmdm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzmdm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;8\\\/3\\\/11\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;8\\\/3\\\/11\u0022}],\u0022ac\u0022:{\u0022spmdc;8\\\/3\\\/11\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;8\\\/3\\\/11\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EQuetiapine is approved for the treatment of acute mania and depression associated with bipolar disorder, a complex and debilitating illness that has a lifetime prevalence between 1% to 4% in the US [Bowden CL et al. \u003Cem\u003EJ Clin Psychiatry\u003C\/em\u003E 2005]. Data from several posters showed the superiority of extended release quetiapine as a treatment for major depressive disorder and generalized anxiety disorder associated with bipolar I\/II disorders versus placebo in patients aged 18 to 65 years.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Emood disorders clinical trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Epsychopharmacology\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003EQuetiapine is approved for the treatment of acute mania and depression associated with bipolar disorder, a complex and debilitating illness that has a lifetime prevalence between 1% to 4% in the US [Bowden CL et al. \u003Cem\u003EJ Clin Psychiatry\u003C\/em\u003E 2005]. The antipsychotic benefits of quetiapine are thought to derive from its ability to block the dopamine and serotonin type 1 and 2 receptors.\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EData from several posters that were presented during the APA annual meeting showed the superiority of extended release quetiapine as a treatment for major depressive disorder (MDD) and generalized anxiety disorder (GAD) associated with bipolar I\/II disorders (BP I, II) versus placebo in patients aged 18 to 65 years.\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003ECutler A et al. (NR3\u2013006) reported that quetiapine (400\u2013800 mg\/day) significantly (p\u0026lt;0.01) reduced the Young Mania Rating Scale (YMRS) score versus placebo after 3 weeks in BP I patients (\u221214.34 and \u221210.52, respectively; p\u0026lt;0.001).\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EBrecher M et al. (NR3\u2013077) presented data from two time-to-event studies that used quetiapine (400\u2013800 mg\/day) as adjunctive therapy to lithium or divalproex in BP I patients. Time from randomization to a mood event (mania, depression, or mixed) was significantly extended (p\u0026lt;0.001) with adjunctive quetiapine versus lithium\/divalproex+placebo (HR=0.30; 95% CI 0.24, 0.37); 125\/646 (19.3%) of quetiapine patients and 343\/680 (50.4%) of placebo patients experienced a mood event within the 104-week studies.\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EIn a similar study in MDD patients, Datto C et al. (NR3\u2013017) reported that quetiapine (mean 176.6 \u00b1 95.5 mg\/day) significantly (p\u0026lt;0.001) extended the time to a depressive event (HR=0.34; 95% CI 0.25, 0.46); 55\/387 (14.2%) of quetiapine and 132\/384 (34.4%) of placebo patients experienced a depressive event within the 52-week study.\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EWeisler R et al. (NR3\u2013101) reported that in patients with MDD, MADRS scores were significantly (p\u0026lt;0.001) reduced by quetiapine 50 mg (\u221213.56), 150 mg (\u221214.50), and 300 mg (\u221214.18) versus placebo (\u221211.07) after 8 weeks of treatment.\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003ESimilar findings were presented by Suppes T et al. (NR3\u2013124) in BP I \u0026amp; II patients with and without rapid cycling (n=270) who experienced acute depression. After 8 weeks, the mean change in MADRS total score for quetiapine (300 mg\/day) was \u221217.4 versus \u221211.9 in the placebo group (p\u0026lt;0.001).\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EJoyce M et al. (NR3\u2013138) reported that quetiapine 50 and 150 mg\/day, but not 300 mg\/day, significantly (p\u0026lt;0.001) reduced GAD scores (HAM-A) after 8 weeks.\u003C\/p\u003E\n         \u003Cp id=\u0022p-10\u0022\u003EIn a time-to-event study, Katzman M et al. (NR3\u2013140) noted that quetiapine (50\u2013300 mg\/day) significantly (p\u0026lt;0.0001) extended the time to a reoccurrence of a GAD-related event versus placebo (HR =0.19; 95% CI 0.12, 0.31); 22\/216 (10.2%) quetiapine- and 84\/217 (38.9%) placebo-treated patients experienced a GAD-related event within the 52-week study.\u003C\/p\u003E\n         \u003Cp id=\u0022p-11\u0022\u003EThe most common adverse events that were reported with quetiapine were sedation, dry mouth, somnolence, dizziness, headache, fatigue, and weight increase. The authors of these studies concluded that quetiapine offers a safe and well-tolerated treatment for mood disorders that are associated with bipolar disorder in a wide class of individuals.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2008 MD Conference Express\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/8\/3\/11.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzmdm1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}